169871-40-3

Upstream product

• 127251-07-4 (4R,5R)-trans-2,2-dimethyl-4-tert-butyldiphenylsiloxymethyl-5-formylmethyl-1,3-dioxolane 
• 169871-37-8 (4R,5S)-trans-2,2-dimethyl-4-tert-butyldiphenylsiloxymethyl-5-formyl-1,3-dioxolane 
• 169871-38-9 (4R,5R)-trans-2,2-dimethyl-4-tert-butyldiphenylsiloxymethyl-5-ethenyl-1,3-dioxolane 
• 169871-36-7 (4R,5R)-trans-2,2-dimethyl-4-tert-butyldiphenylsiloxymethyl-5-hydroxymethyl-1,3-dioxolane 
• 169871-39-0 (4R,5R)-trans-2,2-dimethyl-4-tert-butyldiphenylsiloxymethyl-5-(2-hydroxylethyl)-1,3-dioxolane 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 73346-74-4 (4R,5R)-2,2-dimethyl-1,3-dioxolane-4,5-dimethanol 

Downstream Products

• 169871-44-7 methyl (4R,5R)-trans-7-(2,2-dimethyl-4-(phenylsulfonyl)aminomethyl-1,3-dioxolan-5-yl)-5(Z)-heptanoate 

Relevant academic research and scientific papers

Synthesis of dl-cis-and (4R,5R)-trans-7--5(Z)-heptenoic acid analogues as platelet thromboxane A2 receptor antagonists

The title compounds have been synthesized and their in vitro thromboxane A2(TxA2) receptor antagonist activity evaluated.Both cis and trans isomers (1,2) were shown to specifically inhibit submaximal human platelet aggregation induced by 225 nM U46619 in a dose-dependent manner with an IC50 of 1 μM.The concentration of 1 and 2 required to completely block maximal aggregation induced by 3 μM U46619 was 3 μM. thromboxane A2/ receptor antagonist/ platelet aggregation/ 1,3-dioxolane